Premium
In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia
Author(s) -
Yang PeiChi,
Moreno Jonathan D.,
Miyake Christina Y.,
VaughnBehrens Steven B.,
Jeng MaoTsuen,
Grandi Eleonora,
Wehrens Xander H. T.,
Noskov Sergei Y.,
Clancy Colleen E.
Publication year - 2015
Publication title -
the journal of physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.802
H-Index - 240
eISSN - 1469-7793
pISSN - 0022-3751
DOI - 10.1113/jp271282
Subject(s) - flecainide , catecholaminergic polymorphic ventricular tachycardia , medicine , ventricular tachycardia , anti arrhythmia agents , cardiology , tachycardia , sodium channel blocker , pharmacology , ranolazine , sodium channel , chemistry , atrial fibrillation , ryanodine receptor 2 , organic chemistry , sodium , ryanodine receptor , calcium
Key points The mechanism of therapeutic efficacy of flecainide for catecholaminergic polymorphic ventricular tachycardia (CPVT) is unclear. Model predictions suggest that Na + channel effects are insufficient to explain flecainide efficacy in CPVT. This study represents a first step toward predicting therapeutic mechanisms of drug efficacy in the setting of CPVT and then using these mechanisms to guide modelling and simulation to predict alternative drug therapies.Abstract Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by fatal ventricular arrhythmias in structurally normal hearts during β‐adrenergic stimulation. Current treatment strategies include β‐blockade, flecainide and ICD implementation – none of which is fully effective and each comes with associated risk. Recently, flecainide has gained considerable interest in CPVT treatment, but its mechanism of action for therapeutic efficacy is unclear. In this study, we performed in silico mutagenesis to construct a CPVT model and then used a computational modelling and simulation approach to make predictions of drug mechanisms and efficacy in the setting of CPVT. Experiments were carried out to validate model results. Our simulations revealed that Na + channel effects are insufficient to explain flecainide efficacy in CPVT. The pure Na + channel blocker lidocaine and the antianginal ranolazine were additionally tested and also found to be ineffective. When we tested lower dose combination therapy with flecainide, β‐blockade and CaMKII inhibition, our model predicted superior therapeutic efficacy than with flecainide monotherapy. Simulations indicate a polytherapeutic approach may mitigate side‐effects and proarrhythmic potential plaguing CPVT pharmacological management today. Importantly, our prediction of a novel polytherapy for CPVT was confirmed experimentally. Our simulations suggest that flecainide therapeutic efficacy in CPVT is unlikely to derive from primary interactions with the Na + channel, and benefit may be gained from an alternative multi‐drug regimen.